CALGARY, Alberta, Sept. 02, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of the Company’s Special Meeting of Shareholders held earlier today (the “Meeting”). A total of 72,768,832 common shares of the Company were voted at the Meeting, representing approximately 66% of the total number of issued and outstanding shares.